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Conventional skeletal chondrosarcoma is a bone neoplasm, which is poorly sensitive to anthracyclines-based
chemotherapy. We report on an 18-month-long tumour response to gemcitabine as single agent in a young pa-
tient with an advanced secondary peripheral conventional chondrosarcoma, previously treated unsuccessfully with
anthracyclines, ifosfamide, platinum, etoposide.
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The skeletal chondrosarcoma family represents a hetero-
geneous group of malignant bone mesenchymal tumours
characterised by the production of a chondroid matrix.
They are the third bone sarcoma in incidence, and the
most frequent in adults. There are three main subtypes:
conventional, mesenchymal, and clear-cell. A “dedifferen-
tiated” chondrosarcoma develops in 10-15% of conventional
chondrosarcomas, while mesenchymal chondrosarcoma
is a high-grade, aggressive neoplasm with a natural his-
tory and chemosensitivity that might be close to Ewing
sarcoma, and clear-cell chondrosarcoma is a low-grade
variant [1].
In conventional chondrosarcoma (cCS), the histological
malignancy grade is the main prognostic factor [2]. Grade
1 cCS are characterised by a very low metastatic potential,
and some authors have quite recently suggested a re-
classification of these types as “atypical cartilaginous
tumours” [1]. Grade 2 and 3 cCS are marked by a
higher metastatic potential, with a 10-year survival of
64-86% and 29-55% respectively [3,4].
CCSs are also categorised according to their location
in the bone: a central chondrosarcoma onsets in the me-
dullary cavity, a small percentage of them from a pre-
existing benign lesion known as enchondroma, while a* Correspondence: salvo.provenzano@istitutotumori.mi.it
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unless otherwise stated.peripheral variant arises from the surface of the bone, as
a result of malignant progression of a pre-existing be-
nign (solitary or hereditary) osteochondroma.
Surgery is the mainstay of the treatment of localized
disease. While curettage is acceptable for grade 1 cCS,
wide excision is usually required for higher grade cCS,
with the exception of skull base cCS which may be
treated with radiotherapy. In particular, hadrons can play
an important role in the management of skull base cCS,
and very good outcomes are reported [5].
In surgically treated patients, the benefit of adding
radiotherapy and chemotherapy remains unclear, due to
a lack of prospective trials. Adjuvant radiotherapy and/
or chemotherapy may be proposed to high-risk patients
in conditions of uncertainty. When cCS is advanced, and
a medical therapy is the only option, regimens com-
monly used in other bone sarcomas are employed [6].
Traditionally, chemotherapy has been considered poorly
effective [7], but the low number of cases and the inclu-
sion in available series of conventional (both central and
peripheral), dedifferentiated, mesenchymal, clear-cell his-
totypes does not help to understand the actual chemo-
responsiveness of the disease. Recently, responses to
gemcitabine in combination with docetaxel have been
reported in advanced chondrosarcomas [8].
Hereby, we describe the case of a young woman with a
metastatic, pretreated cCS treated with gemcitabine as a
single agent, after failing to anthracyclines, ifosfamide,
cisplatin, etoposide.ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Contrast-enhanced CT scan performed at the time of diagnosis in December 2009. (a) Presence of a large mass arising from an
osteochondroma (arrow) of the left iliac bone (coronal plane, bone window, venous phase); (b) the primary tumour appears as a poli-lobulated
mass extending within the pelvis, characterised by an irregular, peripheral contrast enhancement and scattered calcification islets (circle) (axial
plane, abdomen window, arterial phase).
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Patient characteristics and medical history
In December 2009, a 38-year old woman, in good gen-
eral conditions, was diagnosed a 17-cm large mass aris-
ing from an osteochondroma of the left iliac bone
(Figure 1). Diagnostic biopsy revealed grade 2 secondary
peripheral cCS (Figure 2). Staging for distant metastases
was negative and no other osteochondromas were found.
No familial history of osteochondromatosis was referred.
Front-line surgery was ruled out because of the extent
of the disease, the major blood vessels and nerves being
involved. In February 2010, chemotherapy with full-dose
doxorubicin plus ifosfamide was administered for 3 cy-
cles, but tumour progression ensued. In April 2010, de-
finitive external beam radiotherapy (total dose 72 Gy)Figure 2 Tru-cut biopsy of the pelvic, primary tumour,
performed in December 2009. Histopathological examination
(HE x5, inset x10): fibrous tissue with nests of cartilaginous
proliferation with hypercellularity and variation in cellular size and
shape, in a focally myxoid matrix. Final diagnosis was G2 peripheral
conventional chondrosarcoma. Radiologic features were not
consistent with the presence of dedifferentiated areas thus
supporting the final diagnosis of a conventional chondrosarcoma.achieved a minor dimensional response and symptom
control.
In July 2012, the disease progressed locally and gave a
single liver metastasis, confirmed on biopsy (Figure 3).
Chemotherapy with 14-day prolonged infusion of high-
dose ifosfamide was administered for one cycle but had
to be withdrawn due to neurotoxicity. Chemotherapy
with cisplatin and etoposide for 2 cycles was given, with
progression of the disease.
In December 2012, in the lack of alternative options, a
fourth-line chemotherapy was started with gemcitabine
(1,000 mg/sqm on day 1,8,15, every 28 days, adminis-
tered intravenously in 30’). By RECIST the disease
looked stable with regard to the pelvic, primary lesion,
while a partial response of the liver lesion was observed
(Figure 4). A significant improvement of symptoms, i.e.
pain and walking impairment due to compression of the
left femoral nerve by the primary tumour, was achieved,Figure 3 CT scan without contrast of the liver at the time of
the first hepatic progression, showing a single metastasis,
characterised by pronounced hypodensity and calcification
islets (axial plane, abdomen window).
Figure 4 Contrast-enhanced CT scan of the liver and the pelvis (axial plane, abdomen window, venous phase). The progressive hepatic
metastasis (black arrow) before (a) and after (b) chemotherapy with cisplatin/etoposide, then a RECIST response after 4 (c) and 9 (d) cycles of
gemcitabine. Pelvis reports (e-h) appear stable (white arrow: primary tumour; asterisk: urinary bladder).
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TTS 50 mcg/h and pregabalin 300 mg twice/day.
Neutropenia G1-G2 was recorded as the only side effect
to gemcitabine.
In September 2013, chemotherapy was interrupted
after 9 cycles as for patient request. Tumour response
was maintained until February 2014 when, after a-14 month
progression-free survival, a disease progression was
observed to the liver and to the abdomen, with the new
appearance of multiple peritoneal metastases. In May
2014, gemcitabine was restarted, with progression at
the following evaluation in September 2014.
Discussion
This is the first report of a response to gemcitabine as
single agent, in a patient with a heavily pre-treated ad-
vanced cCS. The response was marked by a regression
of the tumour and symptomatic improvement. While
high-grade chondrosarcoma subtypes (mesenchymal and
dedifferentiated) can be sensitive to chemotherapy [9],
cCS is usually described as a chemo-refractory disease
[10]. Indeed, in high-grade chondrosarcomas responses
to chemotherapy have been reported to anthracycline-
based chemotherapy combinations, and they are usually
treated with regimens commonly used in high-grade
osteosarcomas, also including cisplatin [7,11-13].Table 1 Summary of available studies reporting on gemcitabi
Type of study Regimen
Merimsky et al., 2000 [25] Prospective Gemcitabine alo
Fox et al., 2012 [8] Prospective Gemcitabine/doc
Italiano et al., 2013 [7] Retrospective Gemcitabine-bas
Legend. RECIST: response evaluation criteria in solid tumour; SD: stable disease; PD:Trials with targeted-therapy have not proven efficacy
so far. The initial enthusiasm on hedgehog inhibitors
coming from pre-clinical studies, on the basis of a strong
activation of the hedgehog pathway in chondrosarcomas,
has been cut down after the results of a phase 2 trial in
which no objective responses were observed [14].
Gemcitabine is a nucleoside analogue of deoxycytidine,
which metabolizes in cell to its active metabolites gemci-
tabine diphosphate (dFdCDP) and gemcitabine triphos-
phate (dFdCTP) [15]. Gemcitabine, both as single agent
or in combination with taxanes, is known to be active in
soft tissue sarcomas, especially leiomyosarcoma and
angiosarcoma [16-19]. As regards bone sarcomas, some
small studies reported objective responses with gemcita-
bine and docetaxel in osteosarcoma and Ewing’s sarcoma
[8,20,21]. Some responses have been reported with
gemcitabine-based regimens in the treatment of chon-
drosarcoma, yet the experience with this combination of
drugs is very limited (data summarised in Table 1).
Though a single case, this is the first report of respon-
siveness of cCS to gemcitabine alone. This patient was
experiencing a progressive disease with worsening symp-
toms before gemcitabine. After starting gemcitabine,
pain and walking impairment quickly improved. Tumour
response was a RECIST partial response to the site of
liver metastasis, and a minor tumour shrinkage of thene in the treatment of chondrosarcomas (all histotypes)
Patients (n) Best response (RECIST)
ne 3 2 SD, 1 PD
etaxel 25 2 PR, 14 SD, 9 PD
ed combinations n/a 3 PR
progressive disease; PR: partial response; n/a: not available.
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lasting. Interestingly, this patient had not responded to
any of the drugs used previously.
To be noted, the patient described in this case report
carried a secondary peripheral chondrosarcoma. Differ-
ently from central variant, secondary peripheral chon-
drosarcomas have distinct molecular features. In fact,
solitary osteochondromas are characterised by homozy-
gous deletion of EXT-1 (exostosin) gene, which is in-
volved in heparan sulfate biosynthesis. This alteration
may lead to a dysregulation of downstream signalling
pathways and, eventually, progression to secondary per-
ipheral chondrosarcoma [22,23]. On this basis, different
targets as compared to primary central chondrosarcoma
have been identified [24] in secondary peripheral chon-
drosarcoma and a different chemosensitivity cannot be
excluded. Even if, at least of our knowledge, there are no
data to sustain at present a higher sensitivity to gemcita-
bine in presence of an EXT-1 deletion and the available
reports on the activity of gemcitabine/docetaxel in chon-
drosarcoma do not go into details on the chondrosar-
coma subtype, this cannot be ruled out.
Conclusion
We add to anecdotal evidence that gemcitabine-based
chemotherapy may be active in cCS. This needs to be
confirmed through prospective studies targeted to cCS,
without the confounding factor of other histotypes.
Whether the combination of docetaxel and gemcitabine
can be more active than gemcitabine single agent in cCS
is left to understand, considering the extra-toxicity im-
plied by the combination in comparison to single-agent
gemcitabine.
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